More recently, DMD deletions were demonstrated in 25 of 40 (63%) high-grade myogenic cancers using SNP analysis, including 19 of 29 (66%) gastrointestinal stromal tumors, 3 of 4 (75%) rhabdomyosarcomas (RMS), and 3 of 7 (43%) leiomyosarcomas28. The gene discussed is DMD; the disease is rhabdomyosarcoma.